Browse our archive of webinars on pharmaceutical and biomedical research from collaborations between pharmaceutical companies, government, biotechnology companies and academia to create new drug discovery opportunities.
DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
DATE: May 17, 2018TIME: 9:00AM PSTLearn how to provide the greatest protection for you and your evidence with the latest enclosures designed specifically for forensic labs. This w...
DATE: April 17, 2018TIME: 8:00AM PST, 11:00AM ESTRecently, much research has focused on obtaining 3D brain organoids in an attempt to better recapitulate brain development and function...
Antibody drug conjugates (ADCs) represent a novel method to deliver a drug to diseased cell using the specific antigen-binding capability and internalization process. Antibodies that do not i...
GPCRs constitute the largest receptor family in the human genome. Over the years they have proven themselves to be druggable targets accounting for about 1/3 of all drugs on the market today....
There is an acute shortage of organs due to disease, trauma, congenital defects, and most importantly, age related maladies. The synthetic materials used in tissue engineering applications to...
Structure based drug design is now well established as a highly efficient approach in pharmaceutical research. The approach uses atomic level detail structures of target proteins, most...
G-protein coupled receptors (GPCRs) represent the single largest class of druggable targets in the human genome. Of the 390 or so druggable and non-olfactory human GPCRs there exist many whic...
Preterm birth (PTB) is the leading cause of infant mortality and morbidity worldwide. Both preterm labor and neonatal injuries have been linked to inflammation. Of all mediators of inflammati...
The field of melanoma has been transformed by the parallel development of effective immune and targeted therapies. There is now strong evidence of cross-talk between oncogenic signaling...
Pharmacogenomics has emerged as an early use case of precision medicine. Delivering this new clinical data to clinicians in a ready to use format can be challenging. This talk wil...
The path form biomarker discovery to conversion to a clinically useful companion diagnostic test presents many challenges. The talk will outline the regulatory requirements to developing a su...
Vaccibody has developed a unique platform technology able to substantially potentiate vaccines by an inherent mechanism that attract, activate and deliver antigens to antigen presenting cells...
Heart failure (HF) is a major problem for our contemporary societies in terms of prevalence, mortality and cost. Natriuretic peptides are recognized biomarkers for the diagnosis of HF but als...
Rapid, accurate estimation of relative ligand affinities offers the potential to allow computational methods to direct drug design and development. Towards this goal we have developed t...
In the last years a number of advanced nanotechnologies have been proposed developed for the administration of drugs (nanomedicines for drug delivery), in order to provide possibilities...
Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutations in the Methyl CpG Binding Protein 2 (MECP2) gene. In mouse models of RTT, deficits in long-term potentiation (LTP) at...
Precision medicine allows for prediction of drug response and tailoring drug therapy based on genetic variability. This talk will provide examples of precision medicine initiatives at the Uni...
Therapies that activate the host immune system have shown tremendous promise for a wide variety of solid tumors. However, in most cancer types, fewer than half of patients respond to these th...
The distinction between "complementary" and "companion" diagnostics tests confuse many physicians and healthcare professionals. Panelists Professor Thomas Webster (Northea...
There are many tumor biomarkers but, they mostly reflect tumor mass or past growth, when what is more important is to obtain an indication of future growth and therapy response.Proliferat...
One-third of FDA-approved drugs target G protein-coupled receptors (GPCRs), transmembrane cell surface proteins that recognize small molecules and polypeptides with diverse chemical scaffolds...
This lecture introduces the evolving paradigm of Molecular Pathological Epidemiology (MPE) as simply as possible. Any given human disease represents fundamentally heterogeneous process,...
We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one...